MarketCapExport financials
AVITA Medical (RCEL)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
AVITA Medical Income Statement 2025-2011 | RCEL
Brief overview of revenue and earnings at AVITA Medical
The conclusions below are based on five years of reported results. According to figures from AVITA Medical, revenue changed from $14.3 million to $71.6 million over five years. The five-year change reached +402.1%, while CAGR stood at 38.1%. This pace points to rapid expansion of the business.
Gross profit changed from $11.3 million to $58.8 million (+421%). Cost of revenue developed more favorably than sales, supporting gross profitability. Gross profit as a share of revenue changed from 79.2% to 82.1%. The margin shift points to a more favorable sales-and-cost structure.
The five-year EBITDA result moved by +4.8%: from −42.2 million dollars to −40.2 million dollars. EBITDA lagged revenue, showing weaker operating momentum. The EBITDA share of revenue changed from −296% to −56.1%. The business generated more EBITDA from each unit of revenue.
The final result was −$42 million initially and −$48.6 million in the final year. The period ended with a larger loss than it began with.
Market capitalization changed from 432 million dollars to 104 million dollars (−76%). Investors responded cautiously to the improvement in the business.
Financial takeaway
The results contain several connected negative signals. The financial profile benefits from sales growth, an improving EBITDA margin and improving gross profitability. The most visible risks are declining capitalization, declining net profitability and a narrow EBITDA buffer. Future reports should be judged by revenue momentum, margins, and the conversion of sales into net income.
Annual Income Statement AVITA Medical
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
104 M | 229 M | 443 M | 224 M | 241 M | 432 M | 376 M | 58.1 M | 50.9 M | 42 M | 26 M | 39.2 M | 45.2 M | 52.3 M | - |
Shares |
27.9 M | 25.9 M | 25.3 M | 25 M | 24.9 M | 20.3 M | 12.7 M | 9.37 M | 7.65 M | 5.72 M | 4.17 M | 3.84 M | 3.55 M | 2.81 M | - |
Historical Prices |
3.72 | 8.84 | 17.5 | 8.96 | 9.67 | 24.7 | 42.8 | 9.4 | 4.85 | 8.6 | 7.85 | 6.4 | 11.8 | 13.2 | - |
Net Income |
-48.6 M | -61.8 M | -35.4 M | -26.7 M | -14.4 M | -42 M | -24.6 M | -12.1 M | -8.85 M | -5.81 M | -5.45 M | -4.85 M | -7.39 M | -7.77 M | -1.92 M |
Revenue |
71.6 M | 64.3 M | 50.1 M | 34.4 M | 14 M | 14.3 M | 5.4 M | 881 K | 907 K | 748 K | 2.11 M | 2.53 M | 2.57 M | 3.43 M | 3.34 M |
Cost of Revenue |
12.8 M | 9.09 M | 7.78 M | 6.04 M | 1.9 M | 2.97 M | 1.27 M | 546 K | - | - | - | - | - | - | - |
Gross Profit |
58.8 M | 55.2 M | 42.4 M | 28.4 M | 12.1 M | 11.3 M | 4.21 M | 505 K | 519 K | 448 K | 1.53 M | 1.89 M | 1.95 M | 2.46 M | 2.36 M |
Operating Income |
-42.5 M | -56.6 M | -42.7 M | -27.5 M | -14.4 M | -42.7 M | -25.5 M | -13.8 M | - | - | - | - | - | - | - |
Interest Expense |
5 M | 5.36 M | 1.14 M | 16 K | 17 K | 33 K | 27 K | 21 K | - | - | - | - | - | - | - |
EBITDA |
-40.2 M | -55.5 M | -42 M | -26.9 M | -14.1 M | -42.2 M | -24.8 M | -13 M | -14.8 M | -8.4 M | -6.07 M | -6.74 M | -8.56 M | -6.67 M | -4.71 M |
Operating Expenses |
101 M | 112 M | 86.4 M | 59.1 M | 27.1 M | 54 M | 29.3 M | 13.7 M | 15.5 M | 10.7 M | 7.66 M | 8.7 M | 10.6 M | 9.65 M | 7.72 M |
General and Administrative Expenses |
27.4 M | 33.2 M | 28.3 M | 23.3 M | 11 M | 34.6 M | 12.7 M | 5.29 M | 9.29 M | 5.58 M | 3.41 M | 5.48 M | 5.05 M | 5.65 M | 5.25 M |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement AVITA Medical
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
30.9 M | 30.7 M | 30.5 M | 848 K | 28.4 M | 26.4 M | 26.3 M | 88.4 K | 26 M | 25.8 M | 25.6 M | 49.3 K | 25.4 M | 25.2 M | 25.2 M | 27.8 M | 25 M | 25 M | 24.9 M | 24.9 M | 22.7 M | 21.6 M | 21.5 M | 21.4 M | 21.5 M | 21.6 M | 21.5 M | 18.7 M | 18.7 M | 18.7 M | 18.3 M | 14.2 M | 13.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-6.22 M | -7.66 M | -10.6 M | -11.6 M | -13.2 M | -9.92 M | -13.9 M | -11.6 M | -16.2 M | -15.4 M | -18.7 M | -7.06 M | -8.71 M | -10.4 M | -9.22 M | -5.35 M | -5.59 M | -6.26 M | -9.46 M | -4.72 M | -6 M | -5.64 M | -10.2 M | -12.9 M | -10.2 M | -5.64 M | -10.2 M | -7.62 M | -3.57 M | -7.62 M | -6.18 M | -6.27 M | -5.03 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
25.9 M | 21.5 M | 19.1 M | 17.4 M | 16.9 M | 18.2 M | 18.3 M | 18.2 M | 19.4 M | 15.2 M | 11.1 M | 14.2 M | 13.6 M | 11.8 M | 10.6 M | 9.46 M | 9.09 M | 8.34 M | 7.54 M | 10.3 M | 8.76 M | 5.1 M | 5.06 M | 3.88 M | 5.06 M | 5.1 M | 5.06 M | 2.46 M | 3.25 M | 2.46 M | 1.71 M | 1.04 M | 269 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
4.17 M | 3.94 M | 3.52 M | 3.3 M | 3.19 M | 3.47 M | 2.83 M | 2.28 M | 3.19 M | 2.11 M | 1.51 M | 1.8 M | 2.11 M | 2.2 M | 1.67 M | 1.35 M | 1.53 M | 1.39 M | 1.78 M | 2.05 M | 2.15 M | 821 K | 929 K | 874 K | 929 K | 821 K | 929 K | 505 K | 619 K | 505 K | 292 K | 242 K | 232 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
21.9 M | 17.8 M | 15.7 M | 14.3 M | 13.9 M | 14.9 M | 15.7 M | 16.1 M | 16.4 M | 13.1 M | 9.59 M | 12.4 M | 11.5 M | 9.55 M | 8.88 M | 8.11 M | 7.56 M | 6.95 M | 5.76 M | 8.25 M | 6.62 M | 4.28 M | 4.13 M | 3 M | 4.13 M | 4.28 M | 4.13 M | 1.95 M | 2.63 M | 1.95 M | 1.42 M | 798 K | 37 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-2.63 M | -6.86 M | -8.8 M | -10.4 M | -9.15 M | -11.1 M | -11.8 M | -9.96 M | -13.8 M | -15.6 M | -17.2 M | -12.3 M | -9.31 M | -11.2 M | -9.91 M | -5.91 M | -5.75 M | -6.36 M | -9.49 M | -4.7 M | -5.99 M | -5.63 M | -10.2 M | -13 M | -10.2 M | -5.63 M | -10.2 M | -7.49 M | -3.66 M | -7.49 M | -6.68 M | -6.3 M | -5.06 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
-2.05 M | 688 K | -395 K | 20 K | -2.75 M | 2.48 M | -791 K | -315 K | -1.07 M | 1.61 M | -66 K | 6.34 M | 615 K | 801 K | 725 K | - | 6 K | 4 K | - | 2 K | 7 K | 4 K | 4 K | 121 K | 7 K | 3 K | 7 K | -246 K | 11 K | 11 K | 5 K | 5 K | 6 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-2.43 M | -6.66 M | -8.6 M | -10.2 M | -9 M | -11 M | -11.7 M | -9.92 M | -13.8 M | -15.6 M | -17.2 M | -12.3 M | -9.3 M | -11.2 M | -9.9 M | -5.9 M | -5.74 M | -6.35 M | -9.45 M | -4.67 M | -5.96 M | -5.6 M | -10.2 M | -12.9 M | -10 M | -5.26 M | -10 M | -7.4 M | -3.59 M | -7.49 M | -6.68 M | -6.3 M | -5.06 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
24.6 M | 24.6 M | 24.5 M | 24.7 M | 23 M | 26.1 M | 27.5 M | 26.1 M | 30.2 M | 28.7 M | 26.8 M | 24.7 M | 21 M | 21.2 M | 19.4 M | 15 M | 14.2 M | 13.9 M | 16 M | 13.4 M | 13.2 M | 10.4 M | 14.9 M | 16.5 M | 14.9 M | 10.4 M | 14.9 M | 10.5 M | 8.34 M | 10.5 M | 9.34 M | 8.85 M | 6.96 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
6.31 M | 5.97 M | 6.06 M | 7.09 M | 7.23 M | 6.67 M | 6.39 M | 7.12 M | 9.59 M | 7.52 M | 8.96 M | 7.75 M | 6.12 M | 6.16 M | 8.3 M | 5.32 M | 5 M | 5.47 M | 7.53 M | 5.28 M | 5.42 M | 3.4 M | 8.3 M | 9.71 M | 8.3 M | 3.4 M | 5.54 M | 3.93 M | 3.42 M | 3.93 M | 3.65 M | 3.4 M | 2.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company AVITA Medical (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Medical devices industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Abbott Laboratories
ABT
|
$ 110.59 | 0.07 % | $ 193 B |  USA |
 |
EDAP TMS S.A.
EDAP
|
- | - | $ 162 M |  France |
 |
Align Technology
ALGN
|
$ 174.54 | 0.16 % | $ 12.7 B | USA |
 |
TELA Bio
TELA
|
$ 0.83 | -4.37 % | $ 39 M | USA |
 |
Edwards Lifesciences Corporation
EW
|
$ 104.0 | -0.68 % | $ 60.8 B | USA |
 |
Avinger
AVGR
|
- | -20.74 % | $ 369 K | USA |
 |
CONMED Corporation
CNMD
|
$ 51.21 | -1.42 % | $ 1.59 B | USA |
 |
Medtronic PLC
MDT
|
$ 101.59 | -1.17 % | $ 130 B | USA |
 |
MiMedx Group
MDXG
|
$ 3.37 | 1.36 % | $ 498 M | USA |
 |
ThermoGenesis Holdings
THMO
|
- | -25.84 % | $ 171 K | USA |
 |
Talis Biomedical Corporation
TLIS
|
- | 3.55 % | $ 7.96 M | USA |
 |
Myomo
MYO
|
$ 1.32 | -5.71 % | $ 55.2 M | USA |
 |
Insulet Corporation
PODD
|
$ 148.03 | -1.19 % | $ 10.4 B | USA |
 |
Profound Medical Corp.
PROF
|
$ 7.66 | 4.36 % | $ 232 M |  Canada |
 |
Quanterix Corporation
QTRX
|
$ 3.3 | -2.51 % | $ 141 M | USA |
 |
Viveve Medical
VIVE
|
- | -15.35 % | $ 1.71 M | USA |
 |
Smith & Nephew plc
SNN
|
$ 30.96 | -0.29 % | $ 26.8 B |  Britain |
 |
Sensus Healthcare
SRTS
|
$ 3.42 | 7.39 % | $ 55.8 M | USA |
 |
Stryker Corporation
SYK
|
$ 324.18 | -0.48 % | $ 124 B | USA |
 |
Tactile Systems Technology
TCMD
|
$ 26.61 | 0.08 % | $ 609 M | USA |
 |
TransMedics Group
TMDX
|
$ 91.02 | -2.95 % | $ 3.09 B | USA |
 |
SmileDirectClub
SDC
|
- | -53.45 % | $ 9.71 M | USA |
 |
Viemed Healthcare
VMD
|
$ 9.04 | 1.01 % | $ 352 M | USA |
 |
Varex Imaging Corporation
VREX
|
$ 18.45 | 0.03 % | $ 764 M | USA |
 |
Acutus Medical
AFIB
|
- | -26.83 % | $ 2.62 M | USA |
 |
Vivos Therapeutics
VVOS
|
$ 0.09 | -8.14 % | $ 925 K | USA |
 |
BIOLASE
BIOL
|
- | -13.19 % | $ 166 K | USA |
 |
SeaSpine Holdings Corporation
SPNE
|
- | 0.28 % | $ 270 M | USA |
 |
Xtant Medical Holdings
XTNT
|
$ 0.28 | -0.68 % | $ 39.1 M | USA |
 |
Zimmer Biomet Holdings
ZBH
|
$ 107.39 | -0.87 % | $ 21.3 B | USA |
 |
Apollo Endosurgery
APEN
|
- | - | $ 475 M | USA |
 |
NuVasive
NUVA
|
- | - | $ 2.07 B | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
$ 0.37 | 59.63 % | $ 24 M |  Israel |
 |
Penumbra
PEN
|
$ 321.48 | -0.11 % | $ 12.5 B | USA |
 |
Conformis
CFMS
|
- | - | $ 16.4 M | USA |
 |
ViewRay
VRAY
|
- | 1.54 % | $ 468 M | USA |
 |
Medigus Ltd.
MDGS
|
- | 10.28 % | $ 55.5 M | Israel |
 |
Boston Scientific Corporation
BSX
|
$ 44.68 | 1.49 % | $ 66.1 B | USA |
 |
Cutera
CUTR
|
- | -10.19 % | $ 1.99 M | USA |
 |
Neovasc
NVCN
|
- | - | $ 111 M | Canada |
 |
Vapotherm
VAPO
|
- | 6.72 % | $ 34 M | USA |
 |
Nevro Corp.
NVRO
|
- | - | $ 217 M | USA |
 |
Venus Concept
VERO
|
- | - | $ 726 K | USA |
 |
Eargo
EAR
|
- | - | $ 10.2 M | USA |
 |
Sientra
SIEN
|
- | -16.59 % | $ 10.3 M | USA |
 |
Silk Road Medical, Inc
SILK
|
- | - | $ 1.07 B | USA |
 |
Surgalign Holdings
SRGA
|
- | -32.98 % | $ 1.68 M | USA |
 |
Cardiovascular Systems
CSII
|
- | 0.15 % | $ 844 M | USA |
 |
ShockWave Medical
SWAV
|
- | - | $ 12.3 B | USA |
 |
Inari Medical
NARI
|
- | - | $ 4.23 B | USA |